Changeflow GovPing Pharma & Drug Safety Anti-C5 Antibody, C5 iRNA Dosing Regimens, Comp...
Routine Notice Added

Anti-C5 Antibody, C5 iRNA Dosing Regimens, Complement Diseases

Email

Summary

Anti-C5 Antibody, C5 iRNA Dosing Regimens, Complement Diseases

Archived snapshot

Apr 10, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

ANTI-C5 ANTIBODY/C5 IRNA DOSING REGIMENS FOR TREATING C5-ASSOCIATED DISEASES

Application US20260097063A1 Kind: A1 Apr 09, 2026

Inventors

Umesh Chaudhari, Kuan-Ju Lin, Lorah Perlee, George D. Yancopoulos

Abstract

The present disclosure includes methods of treating C5-associated disease or disorder, such as myasthenia gravis, with a combination that includes an antibody or antigen-binding fragment thereof that binds specifically to C5 and a C5 iRNA which is a glycoconjugate that includes a ligand having terminal N-Acetylgalactosamine (GalNAc) residues and/or N-acetylglucosamine (GlcNAc) residues; or with the C5 iRNA monotherapy.

CPC Classifications

A61K 31/7125 A61K 31/122 A61K 31/198 A61K 31/4402 A61K 31/4709 A61K 31/475 A61K 31/519 A61K 31/616 A61K 31/727 A61K 33/06 A61K 38/13 A61K 39/3955 A61P 21/04 C07K 16/18 C12N 15/113 A61K 2039/54 A61K 2039/545 A61K 2039/55 C12N 2310/14 C12N 2310/315 C12N 2310/321 C12N 2310/322 C12N 2310/351

Filing Date

2025-10-01

Application No.

19347304

View original document →

Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Instrument
Notice

Get alerts for this source

We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!